Microcrystalline Diketopiperazine Particles for Pulmonary Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pulmonary drug delivery systems face challenges such as drug instability, inefficient absorption, and difficulty in overcoming natural barriers in the lungs, leading to inconsistent and low potency of drugs when administered orally or through inhalation.
Innovation Solution
The development of microcrystalline diketopiperazine (DKP) particles with a high capacity for drug adsorption, which are used to create powders with high drug content. These particles have a hollow spherical structure and are produced through methods involving high shear mixing and spray drying, allowing for improved drug delivery to the lungs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If drugs are administered orally, then ease of administration and patient compliance are improved, but drug instability and absorption efficiency deteriorate
Solution Approach 1:
The patent changes the physical and chemical parameters of the drug by converting it into a microparticulate form with specific surface area and porosity characteristics. This transformation allows the drug to withstand gastrointestinal conditions while maintaining stability, thus resolving the contradiction between ease of oral administration and drug stability.
Solution Approach 2:
The patent creates composite microparticulate structures that combine the drug with carrier materials having specific physical properties. These composite particles provide both the ease of oral administration and the stability needed to survive gastrointestinal conditions, addressing the contradiction between these two requirements.
2Productivity
If drugs are delivered to the lungs via inhalation, then absorption efficiency is improved, but difficulty in overcoming natural barriers and achieving uniform delivery worsens
Solution Approach 1:
The patent creates microparticles with locally optimized properties - specific surface area, porosity, and size distribution - that are tailored to navigate the respiratory tract barriers effectively. These localized quality enhancements enable the particles to overcome ciliary barriers and reach target lung regions, resolving the contradiction between absorption efficiency and delivery difficulty.
Solution Approach 2:
The patent employs dynamic control of particle properties including size distribution and surface characteristics that can adapt to different stages of inhalation and lung deposition. This dynamic approach allows the microparticles to effectively navigate respiratory barriers while maintaining high absorption efficiency at the target site.
3Device complexity
If conventional pulmonary delivery systems are used, then drug delivery is simplified, but drug content per dose and potency deteriorate
Solution Approach 1:
The patent creates microparticulate copies or replicas of ideal drug delivery vehicles with optimized surface area to volume ratios. These microparticle copies maintain the simplicity of conventional delivery systems while dramatically increasing the drug content per dose through their enhanced surface properties and porosity, thus resolving the contradiction between simplicity and potency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of microcrystalline DKP particles enables increased drug content in smaller powder doses, facilitating more effective drug delivery to the lungs while overcoming the challenges of drug instability and absorption inefficiency.
Implementation Method 1
microcrystalline diketopiperazine (DKP) particles with a high capacity for drug adsorption
Implementation Method 2
produced through methods involving high shear mixing and spray drying
Data Source
AI summary
Disclosed herein are DKP microcrystals made by an improved method where they do not irreversibly self-assemble into microparticles. The microcrystals can be dispersed by atomization and re-formed by spray drying into particles having spherical shell morphology. Active agents and excipients can be incorporated into the particles by spray drying a solution containing the components to be incorporated into microcrystalline diketopiperazine particles. In particular, the microcrystalline particle compositions are suitable for pulmonary drug delivery of one or more peptides, proteins, nucleic acids and/or small organic molecules.